New research suggests that levels of ERCC1 -- an enzyme that helps repair cisplatin-related DNA damage -- offer a predictive marker of survival in squamous carcinoma of the head and neck. The findings might eventually help guide treatment selection for patients with recurrent and metastatic disease.